GLP-1s Reshape Confectionery Demand, Driving Innovation in Functional & Portioned Products

London, United Kingdom — 24 June 2026

The confectionery sector is navigating a significant shift driven by the increasing adoption of GLP-1 receptor agonist medications. Initial market anxieties regarding declining sales appear largely unfounded, with the global confectionery market continuing its robust growth trajectory, anticipated to reach £511.9 billion in revenue by 2026, according to Statista. Instead, GLP-1s are catalyzing a profound change in consumer behaviour and product demand.

Key players are already reporting direct impacts. Hershey's CEO, Kirk Tanner, noted in Q1 2026 that sales of mints and chewing gums, particularly their Ice Breakers brand, increased by over 8%. This growth is attributed to the 'Ozempic breath' side-effect associated with GLP-1 usage, a phenomenon also observed across European markets like the UK, France, and the Netherlands, as confirmed by Circana's Ananda Roy. This signals an immediate, albeit niche, commercial opportunity arising from medication side effects.

Beyond specific side-effect driven demand, a broader reformulation window is opening. GLP-1 users are actively seeking healthier alternatives, including reduced-sugar, functional, and portion-controlled confectionery. Circana data indicates a clear shift away from high-calorie options towards products offering protein, fibre, and sustained energy. Brands are responding with innovations such as low-sugar Snickers, 70% cocoa KitKats, and smaller Cadbury bar formats. This consumer-led pivot demands that manufacturers re-evaluate their portfolios for permissible indulgence.

Crucially, this trend is not about total abstinence but about altered consumption. GLP-1 users, even post-treatment, exhibit persistent scrutiny of product labels. With 59% of European users paying closer attention to ingredients, transparency and clear communication of nutritional benefits are paramount. This extends to simplifying ingredient lists and highlighting naturally derived components or specific functional claims. The industry must adapt to a consumer base that eats less but demands more nutritional value per bite, and expects greater honesty from brands.

What this means for United Kingdom

UK manufacturers and brand owners face a dual opportunity: servicing specific GLP-1 side-effect needs and realigning portfolios for long-term health-conscious trends. Demand for mints and gums is currently elevated, offering a short-term sales uplift. More critically, brand owners must accelerate reformulation efforts to meet the growing demand for low-sugar, high-fibre, and protein-enriched confectionery, aligning with tighter compliance around 'HFSS' (high fat, sugar, salt) foods. This presents a competitive advantage for agile manufacturers prepared to invest in R&D for novel ingredients and smaller, premium portion formats. Retailers like Boots and Holland & Barrett will prioritise stocked products that clearly communicate functional benefits and align with evolving health narratives, putting pressure on established brands to adapt quickly or risk ceding market share.

Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.